Inger Johansson

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Inger Johansson, Mikael Oscarson, Qun‐Ying Yue et al. · Molecular Pharmacology · 1994 · 429 citations

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

Eleni Aklillu, Irene Persson, Leif Bertilsson et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 395 citations

Ethanol-, fasting-, and aceton-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies

Inger Johansson, Gunilla Ekstroem, Bob J. Scholte et al. · Biochemistry · 1988 · 317 citations

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

Marja­‐Liisa Dahl, Inger Johansson, Leif Bertilsson et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 313 citations